Oncimmune shares extend losses as it awaits results from key NHS lung cancer screening trial

In results for the six months to 30 November 2018, the AIM-listed firm posted a pre-tax loss of £3.85mln, wider from the £2.83mln loss recorded a year earlier, although revenues rose to £121,000 from £77,000

More From BioPortfolio on "Oncimmune shares extend losses as it awaits results from key NHS lung cancer screening trial"